DexCom earnings beat by $0.03, revenue topped estimates
Accenture plc (NYSE:ACN) Chair and CEO Julie Spellman Sweet recently sold a significant portion of her holdings in the company. According to a recent SEC filing, Sweet disposed of 2,284 Class A ordinary shares on April 11, 2025, through multiple transactions. The shares were sold at prices ranging from $278.9764 to $284.4813, totaling approximately $643,253. The timing is notable as Accenture’s stock, currently trading at $289.79, sits near its 52-week low of $275.01, according to InvestingPro data.
Following these transactions, Sweet retains ownership of 9,965 shares in Accenture. The sales were part of a pre-arranged trading plan, as noted in the filing, ensuring transparency and compliance with regulatory standards. The company maintains strong financial health with a "GOOD" overall rating from InvestingPro, which offers comprehensive analysis through its Pro Research Report.
Investors often pay close attention to insider transactions like these, as they can provide insights into the executive’s perspective on the company’s stock valuation. With analyst targets ranging from $280 to $415 and the stock currently trading below InvestingPro’s Fair Value estimate, investors seeking deeper insights can access additional analysis and 12 exclusive ProTips through InvestingPro.
In other recent news, Accenture reported strong second-quarter results for fiscal year 2025, with both revenue and earnings per share (EPS) exceeding consensus estimates. Despite this positive performance, operating income fell slightly below expectations. Following these results, Accenture updated its guidance, projecting a 5% to 7% growth range for the full year 2025, an increase from the previous forecast. In response to these developments, Piper Sandler adjusted its price target for Accenture from $396 to $364, maintaining an Overweight rating, while Baird reduced its target from $390 to $372, keeping an Outperform rating. Mizuho (NYSE:MFG) also revised its price target from $398 to $365 but continued to rate Accenture as Outperform. Analysts from these firms expressed confidence in Accenture’s market position, highlighting its strengths in next-generation technology solutions like Generative AI. BMO Capital Markets maintained a Market Perform rating with a $355 price target, noting the importance of contract durations in revenue assessments. Piper Sandler identified Accenture as a potential beneficiary of AI initiatives, which could enhance its value for clients.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.